Parkside Financial Bank & Trust’s KalVista Pharmaceuticals KALV Stock Holding History

Parkside Financial Bank & Trust’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-40	Closed	-$805	–	2755
2026 Q1	$805	Hold	40	–	–	﹤0.01%	2426
2025 Q4	$646	Hold	40	–	–	﹤0.01%	2500
2025 Q3	$488	Hold	40	–	–	﹤0.01%	2578
2025 Q2	$453	Buy	+40	New	+$489	﹤0.01%	2598

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Parkside Financial Bank & Trust's KALV Position: Q2 2026 in Review

Parkside Financial Bank & Trust sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 40 shares — an estimated $805 sold.

Parkside Financial Bank & Trust first reported a position in KALV in Q2 2025 and held it in 4 quarters. The position peaked at $805 in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Parkside Financial Bank & Trust reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Parkside Financial Bank & Trust sold 40 KalVista Pharmaceuticals shares in Q2 2026, an estimated $805.
Parkside Financial Bank & Trust first reported a position in KalVista Pharmaceuticals in Q2 2025 and held it in 4 quarters.
Parkside Financial Bank & Trust's KalVista Pharmaceuticals position peaked at $805 in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.